Changes in Hong Kong stocks | Jingtai Holdings (02228) rose more than 8% in early trading, and the company's business has been extended from AI Pharmaceuticals to the AI4S platform

The Zhitong Finance App learned that Jingtai Holdings (02228) rose more than 8% in early trading. As of press release, it had risen 6.98% to HK$10.12, with a turnover of HK$129 million.

According to the news, at the beginning of last month, Mirxes, an early cancer screening company, announced a cooperation with AI pharmaceutical platform company Jingtai Technology. The two sides aim to integrate their respective advantages in early detection and drug development to jointly explore “integrated diagnosis and treatment” solutions for high-incidence cancers in Asia. This move is seen as an important integration experiment in the cancer prevention and control value chain.

Shen Wan Hongyuan released a research report stating that Jingtai Holdings relied on the core technology of “physical computing+AI+ robotics” to establish a complete closed loop of early drug development from algorithms and engines to automated laboratories. The company's business has expanded from AI pharmaceuticals to the broader “AI4S” platform. Its underlying technology can not only accelerate all aspects of innovative drug development, but also has the potential to migrate to new materials and other fields, showing strong technical breadth and platform-based value. The first coverage gives a “buy” rating.